Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2016 Feb;68(2):254–260. doi: 10.1002/acr.22632

Table 2. Phenotypic features of 133 primary SS patients in relation to anti-IFI16 antibody status*.

Phenotypic feature IFI16 positive (n=38) IFI16 negative (n=95) P value
Age (years), mean±SD 55.1±13.8 52.2±12.9 0.27
Female 37 (97) 90 (95) 0.67
Caucasian 21 (55) 44 (47) 0.44
Schirmer <5 mm/5 min 24 (63) 32 (34) 0.003
UWS<0.5 ml/5 min 32 (84) 67 (71) 0.13
WBC<4000 9 (24) 21 (23) 1.0
C4<16 mg/dl 11 (29) 17 (18) 0.17
IgG>1445 mg/dl 28 (74) 47 (49) 0.02
ANA ≥1:320 31 (82) 55 (58) 0.01
SSA (Ro52 and/or Ro60) 28 (74) 70 (74) 1.0
SSB 18 (47) 50 (53) 0.70
Extraglandular disorder 8 (21) 18 (19) 0.81
Germinal center-like structure in biopsy 15 (39) 17 (18) 0.01
Rheumatoid factor 27 (71) 56 (59) 0.24
Focus score, median (25th-75th percentile) 3.4 (2.6-6.4) 2.4 (1.6-3.7) 0.005
*

Except where indicated otherwise, values are the number (%) of patients.

Physician-confirmed diagnoses of Grave's disease, Hashimoto's thyroiditis, interstitial nephritis, primary biliary cirrhosis, autoimmune hepatitis, renal tubular acidosis, glomerulonephritis, and lymphoma

Abbreviations: SS, Sjögren's syndrome; UWS, unstimulated whole saliva flow rate; WBC, white blood count; C4, complement 4; IgG, immunoglobulin G